Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341770 | 0.89 | TSHR (0.46) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL3552780 | 0.86 | CYP4F2 (0.46) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2001481 | 0.84 | TSHR (0.52) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL12338140 | 0.83 | SLC6A4 (0.38) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL3552305 | 0.83 | TSHR (0.44) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL2184188 | 0.81 | TSHR (0.48) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL11948047 | 0.81 | NPC1 (0.50) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL11947932 | 0.80 | CYP3A4 (0.49) | TSHRALDH1A1LMNATP53KDM4E | |
| SCHEMBL7813719 | 0.80 | TSHR (0.52) | TSHRCA12CA1CA2CA7 | |
| SCHEMBL12340228 | 0.80 | KMT2A (0.36) | TSHRKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-7723524-B2 | 8-cyanoquinolonecarboxylic acid derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-0775702-B1 | NOVEL QUINOLONE- OR NAPHTHYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-5935952-A | ANTIBACTERIAL AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0775702-A1 | NOVEL QUINOLONE- OR NAPHTHYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255190-A1 | 8-Cyanoquinolonecarboxylic Acid Derivative | QPCT, ASNS, C3AR1 | TSHR 2894/4885CA12 492/4885CA1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.